Candriam SCA Portfolio holdings
Candriam is a Luxembourg asset manager with sustainable investing at its core, run as a subsidiary of New York Life Investments, with Belgian bank Belfius holding a minority stake. It was previously Dexia Asset Management and took the Candriam name in 2014, short for "Conviction AND Responsibility In Asset Management", after New York Life's asset management arm acquired it. Its funds span bonds, stocks, absolute return strategies and asset allocation, and its portfolios exclude controversial weapons, thermal coal and tobacco. In 2021 it bought a majority stake in the European real estate manager Tristan Capital Partners.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$98.2M |
| 2 |
Meta Platforms (Facebook)
META
|
+$82.9M |
| 3 |
ServiceNow
NOW
|
+$70.4M |
| 4 |
Intel
INTC
|
+$58.4M |
| 5 |
Salesforce
CRM
|
+$54.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$102M |
| 2 |
Palo Alto Networks
PANW
|
+$102M |
| 3 |
AbbVie
ABBV
|
+$68.9M |
| 4 |
Amazon
AMZN
|
+$57M |
| 5 |
NVIDIA
NVDA
|
+$54.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 41.06% |
| 2 | Healthcare | 24.01% |
| 3 | Financials | 9.02% |
| 4 | Communication Services | 7.08% |
| 5 | Consumer Discretionary | 6.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
151
United Therapeutics
UTHR
$25.3B
| $30M | 0.13% |
55,109
+1,425
| +3% | +$737K |
2023 Q1
14 quarters
|
|
152
eBay
EBAY
$52.7B
| $29.5M | 0.13% |
276,902
-5,778
| -2% | -$629K |
2014 Q4
47 quarters
|
|
153
Netflix
NFLX
$257B
| $29.2M | 0.13% |
417,515
-69,049
| -14% | -$5.19M |
2014 Q4
47 quarters
|
|
154
Ecolab
ECL
$85.4B
| $28.5M | 0.13% |
103,259
-88,717
| -46% | -$24.6M |
2014 Q4
47 quarters
|
|
155
Arista Networks
ANET
$261B
| $28.4M | 0.13% |
138,795
+2,066
| +2% | +$389K |
2016 Q4
39 quarters
|
|
156
Oruka Therapeutics
ORKA
$7.12B
| $28.3M | 0.13% |
339,032
-13,684
| -4% | -$1.29M |
2025 Q1
6 quarters
|
|
157
Summit Therapeutics
SMMT
$12.1B
| $28.2M | 0.13% |
1,662,969
+1,130,537
| +212% | +$16.9M |
2024 Q3
8 quarters
|
|
158
CVS Health
CVS
$115B
| $27.7M | 0.12% |
322,096
-2,164
| -0.7% | -$212K |
2014 Q4
47 quarters
|
|
159
Travere Therapeutics
TVTX
$4.95B
| $27.3M | 0.12% |
461,331
-8,934
| -2% | -$546K |
2025 Q1
6 quarters
|
|
160
Bruker
BRKR
$9.21B
| $27M | 0.12% |
415,327
+3,627
| +0.9% | +$214K |
2020 Q4
23 quarters
|
|
161
United Rentals
URI
$70.5B
| $26.7M | 0.12% |
26,595
-3,403
| -11% | -$3.63M |
2017 Q1
38 quarters
|
|
162
CG Oncology
CGON
$6.27B
| $26.7M | 0.12% |
375,362
-93,808
| -20% | -$6.89M |
2025 Q2
5 quarters
|
|
163
Cloudflare
NET
$114B
| $26.7M | 0.12% |
76,607
+18,241
| +31% | +$5.4M |
2022 Q1
18 quarters
|
|
164
Arcutis Biotherapeutics
ARQT
$3.48B
| $26.6M | 0.12% |
1,003,729
+53,890
| +6% | +$1.41M |
2024 Q2
9 quarters
|
|
165
Church & Dwight Co
CHD
$26.4B
| $26.4M | 0.12% |
279,262
+20,133
| +8% | +$1.98M |
2016 Q1
42 quarters
|
|
166
Nike
NKE
$56.1B
| $25.8M | 0.11% |
725,483
+606,441
| +509% | +$24.3M |
2019 Q3
28 quarters
|
|
167
CBRE Group
CBRE
$38.2B
| $25.6M | 0.11% |
198,582
+38,310
| +24% | +$5.49M |
2014 Q4
47 quarters
|
|
168
Target
TGT
$73.1B
| $25.6M | 0.11% |
162,598
-23,119
| -12% | -$3.48M |
2016 Q1
42 quarters
|
|
169
Vaxcyte
PCVX
$10.2B
| $25.5M | 0.11% |
447,260
+239,206
| +115% | +$13.9M |
2026 Q1
2 quarters
|
|
170
Ralph Lauren
RL
$23.1B
| $25.3M | 0.11% |
70,922
-19,005
| -21% | -$7M |
2024 Q4
7 quarters
|
|
171
TJX Companies
TJX
$150B
| $25.3M | 0.11% |
190,321
-161,143
| -46% | -$23.2M |
2014 Q4
47 quarters
|
|
172
Coherent
COHR
$45.7B
| $25.1M | 0.11% |
86,743
-2,343
| -3% | -$703K |
2025 Q2
5 quarters
|
|
173
Darling Ingredients
DAR
$8.58B
| $24.4M | 0.11% |
400,607
+204,945
| +105% | +$12.9M |
2021 Q1
22 quarters
|
|
174
Welltower
WELL
$180B
| $24.4M | 0.11% |
105,485
-194,561
| -65% | -$46M |
2014 Q4
47 quarters
|
|
175
Canadian Imperial Bank of Commerce
CM
$105B
| $24.3M | 0.11% |
218,884
-67,011
| -23% | -$7.82M |
2014 Q4
47 quarters
|
|
Similar funds
Candriam SCA's Q3 2026 Portfolio in Review
As of Q3 2026, Candriam SCA held 699 positions worth $22.5B, up 1.4% from $22.2B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Candriam SCA's Q3 2026 filing shows 21 new, 252 increased, 270 reduced and 51 closed positions. Its largest new stake was Zenas BioPharma: 654,833 shares worth $17.7M. The largest sale was Alphabet (Google) Class A, an estimated $102M.
By sector, the portfolio is most concentrated in Technology at 41% of assets, up from 38% a quarter earlier, followed by Healthcare and Financials.
- Candriam SCA's largest Q3 2026 buy was Zenas BioPharma: 654,833 shares worth $17.7M.
- Candriam SCA added most to Abbott in Q3 2026, an estimated $98.2M increase.
- Candriam SCA's biggest Q3 2026 reduction was Alphabet (Google) Class A, cutting an estimated $102M.
- Candriam SCA fully exited StoneX in Q3 2026, selling an estimated $46.1M.
- Candriam SCA's ten largest holdings make up 34% of its $22.5B portfolio in Q3 2026.
- Candriam SCA opened 21 new positions and closed 51 in Q3 2026.
- Candriam SCA's portfolio value rose 1.4% quarter-over-quarter to $22.5B.
Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.